Immunexpress Group, a Brisbane, Australia and Seattle, USA-based molecular diagnostic company, raised $6m in funding.
The round was led by Debiopharm Diagnostics SA, which is part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group™, with a focus on investment in innovative diagnostic companies.
The company intends to use the funds to advance development of the Immunexpress SeptiCyte® technology and bring one of its late-stage sepsis diagnostic products through to market.
Led by Dr Roslyn Brandon, President and Chief Executive Officer, Immunexpress focuses on improving outcomes for patients with, or at risk of, sepsis, a life-threatening illness caused by the immune system’s response to an infection. It specializes in clinical validation of genomic and proteomic biomarkers, and the translation of these novel biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care (POC).
The company’s SeptiCyte® technology quantifies multiple specific molecular markers from the patient’s own immune system for earlier diagnosis, detection, triage, screening, severity assessment, and for better timing and targeting of drug and other therapies.
FinSMEs
06/03/2014